List of Cell Therapies Companies in Spain - 11

We are now 3PBIOVIAN! 𝗙𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 𝗼𝗻 𝗼𝘂𝗿 𝗻𝗲𝘄 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗮𝗴𝗲, 𝟯𝗣𝗕𝗜𝗢𝗩𝗜𝗔𝗡, 𝘁𝗼 𝘀𝘁𝗮𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝗱 𝗼𝗻 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗻𝗲𝘄𝘀! 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO. Read more here: www.3pbiovian.com ***** 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined track record of 40 years in process development and analytical methods development, complemented by our experience in process scale-up, GMP manufacturing, and commercial supply, we are equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of our clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.

The Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (Ciberdem) is a public state consortium established by the Carlos III Health Institute (Ministry of Economy and Competitiveness). Constituted by 31 elite research groups in 19 associate institutions, it represents the biggest network of scientific diabetes research in Spain. Its objectives are to lead highest standards of research practice and to accelerate the translation of scientific results into clinical application. Ciberdem looks to involve not only the scientific community but also the business sector in R&D investment. The consortium offers companies the possibility of working together on research projects, scientific consultancy, organisation of scientific events and socially responsible corporate actions. Ciberdem divulges its scientific work through multiple actions such as the periodic organisation of scientific seminars and its annual Science Open Day always with the active collaboration of patient associations. In its mision to promote diabetes research Ciberdem has created «Investiga la diabetes», an initiative which seeks to increase awareness of the diabetes problem in Spain. Its objective is to generate active participation from society and business with the aim of collecting funds which will enable the continued promotion and financing of scientific activity to find new means of preventing, diagnosing, treating and curing diabetes. ciberdem.org investigaladiabetes.org

Histocell is a clinical-stage biopharmaceutical company, specialized in developing cell therapy medicaments and novel medical devices for regenerative medicine, with a therapeutic approach focus on the control of oxidative stress. We work to improve people’s quality of life by creating new Cell Therapy medicaments. Our headquarters is located at the Bizkaia Science and Technology Park (Spain), with facilities comprising a 65 m2 GMP certified manufacturing room for cell therapy medicinal products, several laboratories for quality control and R&D activities and a 2000 m2 medical device manufacturing plant. Our team meets the maximum quality standards through GMP and ISO 9001/2000 certifications. Company's pipeline includes medical devices for promotion of Natural Wound Healing (Reoxcare® , Vexoderm®), Dermatologic Tissue Regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®) as well as Cell Therapy programs based on adipose derived mesenchymal stem cells (AMSC) for Bone regeneration and based on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease. Finally, Histocell, as an authorized ATMP manufacturing laboratory, offers Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.

Hospital Sant Joan de Déu (Barcelona) is a teaching hospital specializing in the fields of pediatrics, gynecology and obstetrics. It is located in Barcelona, Catalonia (Spain). It is a privately owned center, concerted by the Catalan Public Health Service, which belongs to the Hospitaller Order of St. John of God, religious organization that manages more than 300 health centers over the world. In 2022, the center has 333 beds and 15 operating rooms. It employs more than 2.800 professionals and attends 3.069 births, 17.184 hospitalizations, 5.210 major ambulatory surgery, and 15.329 surgeries are performed. Hospital Sant Joan de Deu is the largest children's hospital in Spain, one of the top5 in Europe, along with Great Ormond Street (London), Hôpital Necker Enfants Malades (Paris) and Ospedale Meyer (Florence), and the reference point in Health 2.0 in Spain. Since 2009 the hospital is associated with the National Association of Children's Hospitals and Related Institutions (NACHRI), a prestigious organization of children's hospitals working to promote health and access to health care for children, and has over 200 members in the United States, Australia, Canada, Italy, Mexico and Puerto Rico.

At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

OneChain Immunotherapeutics is a spin-off Company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Our strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

Universitat de Barcelona is a Higher Education institution that focuses on academic programs and research.

Viralgen is a CDMOfor AAV production that supportslarge-scale manufacturing, fill-finish, and quality control in a GMP-certified environment